EOS 789
Alternative Names: AP-306 ; EOS-789Latest Information Update: 10 Jan 2025
Price :
$50 *
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Shanghai Alebund Pharmaceuticals
- Class Cardiovascular therapies; Small molecules
- Mechanism of Action Phosphate transport protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hyperphosphataemia
Most Recent Events
- 07 Jan 2025 Alebund Pharmaceuticals plans a phase II trial for Hyperphosphataemia in the US and China
- 13 Dec 2023 Interim efficacy and adverse events data from phase II trial in Hyperphosphataemia released by Alebund Pharmaceuticals
- 14 Sep 2023 Alebund Pharmaceuticals completes a phase II trial in Hyperphosphataemia in China (PO) (NCT05764590)